Recent News

• 03.20.2026 - argenx announces Annual General Meeting of Shareholders on May 6, 2026
• 03.06.2026 - argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
• 02.26.2026 - argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
• 02.26.2026 - argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
• 02.23.2026 - argenx to Present at TD Cowen 46th Annual Healthcare Conference
• 02.19.2026 - argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
• 01.13.2026 - argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

Recent Filings

• 03.20.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.20.2026 - EX-99.1 EX-99.1
• 03.19.2026 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.19.2026 - EX-99.1 EX-99.1
• 03.19.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.06.2026 - EX-99.1 EX-99.1
• 03.06.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.26.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.26.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.26.2026 - EX-99.1 EX-99.1